![MMAE-[d8]](https://resource.bocsci.com/structure/2070009-72-0.gif)
Inquiry Basket
CAS No.:
Cat No.: BADC-00764
4.5 
DBCO-PEG4-GGFG-DX8951 is a drug-linker conjugate for ADC by using DX8951 (Synonyms: Exatecan, a DNA topoisomerase I inhibitor), linked via DBCO-PEG4-GGFG.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
DBCO-PEG4-GGFG-DX8951, a cutting-edge conjugate utilized in targeted drug delivery and bioorthogonal chemistry, offers a myriad of applications. Here are four key applications:
Targeted Drug Delivery: Leveraging the unique capabilities of DBCO-PEG4-GGFG-DX8951, researchers can precisely deliver medications to specific cells or tissues, significantly boosting the effectiveness of therapies. The DBCO moiety facilitates click chemistry with azide-functionalized biomolecules, ensuring meticulous conjugation and delivery. This targeted strategy minimizes off-target effects and mitigates the systemic toxicity of chemotherapeutic agents.
Bioorthogonal Chemistry: A cornerstone of bioorthogonal chemistry, DBCO-PEG4-GGFG-DX8951 enables intricate click reactions that allow for pinpoint modifications of biomolecules within living systems without disturbing native biochemical processes. Scientists utilize this conjugate to selectively label proteins, nucleic acids, and other biomolecules, opening up avenues for studying nuanced biological systems and crafting sophisticated diagnostic tools with unparalleled specificity.
Antibody-Drug Conjugates: DBCO-PEG4-GGFG-DX8951 plays a pivotal role as a linker in the creation of antibody-drug conjugates (ADCs), a revolutionary class of targeted cancer therapies. The PEG4 spacer enhances the solubility and stability of the conjugate, while the GGFG peptide sequence provides a cleavable site for controlled drug release within the target milieu. This innovative approach results in superior treatment outcomes with diminished side effects, offering renewed hope in the fight against cancer.
Theranostics: In the realm of theranostics, DBCO-PEG4-GGFG-DX8951 shines, offering combined therapeutic and diagnostic functionalities for tailored treatment regimens. By coupling this compound with imaging agents, clinicians can monitor drug delivery and therapeutic efficacy in real-time, enabling personalized treatment strategies and enhancing patient outcomes across various diseases, notably cancer. This dual-purpose feature underscores the transformative potential of DBCO-PEG4-GGFG-DX8951 in advancing precision medicine practices.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00608 | MC-GGFG-DX8951 | 1600418-29-8 |
DBCO-PEG4-GGFG-DX8951
Required fields are marked with *
DBCO-PEG4-GGFG-DX8951
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
